Compare, Analyse VENUS REMEDIES with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs TEVA PHARMA (Israel) - Comparison Results

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 VENUS REMEDIES   TEVA PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
TEVA PHARMA
Dec-13
VENUS REMEDIES/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs1262,964-   
Low Rs612,575-   
Sales per share (Unadj.) Rs301.81,701.1-  
Earnings per share (Unadj.) Rs-24.9106.3-  
Cash flow per share (Unadj.) Rs2.5243.8-  
Dividends per share (Unadj.) Rs093.02-  
Dividend yield (eoy) %03.4 0.0%  
Book value per share (Unadj.) Rs293.31,889.6-  
Shares outstanding (eoy) m12.34848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.31.6 19.0%   
Avg P/E ratio x-3.826.1 -14.4%  
P/CF ratio (eoy) x36.711.4 323.4%  
Price / Book Value ratio x0.31.5 21.8%  
Dividend payout %087.5 0.0%   
Avg Mkt Cap Rs m1,1542,348,443 0.0%   
No. of employees `0000.944.9 2.1%   
Total wages/salary Rs m3930-   
Avg. sales/employee Rs Th4,026.132,094.7 12.5%   
Avg. wages/employee Rs Th425.00-   
Avg. net profit/employee Rs Th-331.82,004.9 -16.5%   
INCOME DATA
Net Sales Rs m3,7241,442,497 0.3%  
Other income Rs m230-   
Total revenues Rs m3,7471,442,497 0.3%   
Gross profit Rs m395395,029 0.1%  
Depreciation Rs m338116,598 0.3%   
Interest Rs m35428,333 1.3%   
Profit before tax Rs m-275250,097 -0.1%   
Minority Interest Rs m01,136 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-164,175 0.0%   
Tax Rs m32-3,053 -1.0%   
Profit after tax Rs m-30790,112 -0.3%  
Gross profit margin %10.627.4 38.7%  
Effective tax rate %-11.5-1.2 940.2%   
Net profit margin %-8.26.2 -131.9%  
BALANCE SHEET DATA
Current assets Rs m2,638974,257 0.3%   
Current liabilities Rs m2,305849,635 0.3%   
Net working cap to sales %8.98.6 103.5%  
Current ratio x1.11.1 99.8%  
Inventory Days Days13591 149.2%  
Debtors Days Days4696 48.3%  
Net fixed assets Rs m4,871471,151 1.0%   
Share capital Rs m1233,551 3.5%   
"Free" reserves Rs m3,4960-   
Net worth Rs m3,6191,602,341 0.2%   
Long term debt Rs m1,374737,581 0.2%   
Total assets Rs m7,5093,296,568 0.2%  
Interest coverage x0.29.8 2.3%   
Debt to equity ratio x0.40.5 82.5%  
Sales to assets ratio x0.50.4 113.3%   
Return on assets %0.63.6 17.6%  
Return on equity %-8.55.6 -150.8%  
Return on capital %1.64.9 32.1%  
Exports to sales %00-   
Imports to sales %13.90-   
Net fx Rs m-5170-   
CASH FLOW
From Operations Rs m514229,859 0.2%  
From Investments Rs m-123-81,448 0.2%  
From Financial Activity Rs m-387-275,732 0.1%  
Net Cashflow Rs m4-127,321 -0.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 71.01 Rs / USD

Compare VENUS REMEDIES With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare VENUS REMEDIES With: JUBILANT LIFE SCIENCES  PROCTER & GAMBLE HEALTH  AUROBINDO PHARMA  SANOFI INDIA  ORCHID PHARMA LTD  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views On News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India (The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market (The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On (Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown (The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted (Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Sep 20, 2019 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - NOVARTIS COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS